In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's Ambitions in the Off-Patent World

Executive Summary

The pending purchase of Wyeth will accelerate Pfizer's transformation from a mass marketer of superstar drugs into a diversified supplier of targeted therapies, consumer health, and other health care products. It is a major but incomplete step in the search for new growth drivers as Pfizer's cholesterol drug Lipitor--worth a quarter of the Big Pharma's 2008 revenues--loses exclusivity. The company has also restructured existing operations into six business units, the most intriguing of which is the Established Products Business Unit. That division has pulled together Pfizer's off-patent and branded older products into a $10 billion business, albeit one with declining sales. Its leader, David Simmons has the job of reversing the decline and creating a growth story.

Related Content

Abbott Ups Emerging Markets Ante With Zydus Deal, Established Products Unit
Abbott Ups Emerging Markets Ante With Zydus Deal, Established Products Unit
Is Teva Among Finalists In Bidding For Germany's Ratiopharm? (Part 2 of 2)
Emerging Pharma Markets: Adapt, Diversify, and Persist
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2009
Transforming Pharma's Commercial Capabilities to Drive Maximum Value
Pfizer Bulks Up Its Generics Business
Pfizer Signs Big Bang Deal With Aurobindo For Larger Presence in Generics; Biosimilars Next ?
Pfizer/Wyeth: Industrializing Pharma?
Pfizer/Wyeth: Industrializing Pharma?


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts